◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › D › DBVT

DBV Technologies (DBVT) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-09-19

DBV Technologies (DBVT) operates in the BIOTECHNOLOGY industry and is headquartered in Châtillon, France with about 170 employees. Its market capitalization is roughly $776 million. In the fiscal year ended 2025-12-31, DBVT reported $0M in revenue and ($147M) in net income.

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France.

Interactive charts & full statements → Open the DBVT valuation workbench →

DBVT Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31
Total Revenue	$0M	$0M	$3M	$16M	$5M	$6M	$11M	$15M	$13M	$12M	$8M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Gross Profit	—	($18M)	($7M)	$16M	$5M	($5M)	$11M	$15M	$13M	$12M	$8M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Gross Margin %	—	—	-265.3%	100.0%	100.0%	-82.0%	100.0%	100.0%	100.0%	100.0%	100.0%	36.6%	35.5%	44.0%	52.4%	-38.9%	-35.5%	-67.5%	-86.6%
Operating Income (EBIT)	($181M)	($147M)	($121M)	($76M)	($97M)	($99M)	($159M)	($171M)	($190M)	($174M)	($122M)	($54M)	($30M)	($27M)	($18M)	($9M)	($8M)	($6M)	($8M)
Operating Margin %	—	—	-4693.4%	-486.0%	-1994.9%	-1727.6%	-1408.7%	-1162.8%	-1483.6%	-1510.0%	-1540.6%	-24603.5%	-11622.2%	-10932.8%	-7664.2%	-5760.4%	-3457.0%	-3033.1%	-5753.4%
Net Income	($176M)	($147M)	($114M)	($73M)	($96M)	($98M)	($160M)	($172M)	($190M)	($177M)	($126M)	($49M)	($29M)	($27M)	($17M)	($9M)	($6M)	($5M)	($6M)
Net Margin %	—	—	-4428.2%	-462.4%	-1987.5%	-1713.5%	-1415.0%	-1169.5%	-1484.7%	-1538.3%	-1593.9%	-21969.5%	-11327.9%	-10579.0%	-7382.7%	-5744.5%	-2689.5%	-2382.6%	-4651.3%
EBITDA	($172M)	($139M)	($111M)	($63M)	($83M)	($91M)	($125M)	($168M)	($206M)	($177M)	($126M)	($48M)	($28M)	($30M)	($17M)	($9M)	($6M)	($5M)	($6M)
Earnings Per Share (EPS)	$-2.07	$-1.70	$-1.18	$-0.76	$-1.24	$-1.78	$-2.95	$-3.22	$-3.47	$-7.16	$-5.17	$-2.07	$-1.72	$-1.95	$-1.27	$-0.70	$-0.47	$-0.37	$-0.45
Shares Outstanding (M)	86M	86M	96M	95M	77M	55M	54M	53M	55M	25M	24M	23M	17M	14M	13M	13M	13M	13M	13M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

DBVT Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$0M	$0M	$0M	$0M	$0M	$1M	$0M	$1M
Gross Profit	—	($4M)	($4M)	($4M)	($5M)	$1M	—	$1M
Gross Margin %	—	—	—	—	—	100.0%	—	100.0%
Operating Income (EBIT)	($51M)	($48M)	($45M)	($37M)	($43M)	($27M)	($24M)	($30M)
Operating Margin %	—	—	—	—	—	-5209.0%	—	-2829.1%
Net Income	($50M)	($48M)	($45M)	($33M)	($42M)	($27M)	($23M)	($30M)
Net Margin %	—	—	—	—	—	-5299.2%	—	-2839.7%
EBITDA	($51M)	($46M)	($44M)	($31M)	($38M)	($25M)	($23M)	($29M)
Earnings Per Share (EPS)	$-0.59	$-0.56	$-0.59	$-0.34	$-0.44	$-0.28	$-0.24	$-0.32
Shares Outstanding (M)	86M	86M	77M	96M	96M	96M	—	96M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

DBVT Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31
Cash from Operations (CFO)	($200M)	($121M)	($104M)	($80M)	($56M)	($108M)	($166M)	($148M)	($187M)	($161M)	($66M)	($32M)	($32M)	($24M)	($18M)	($10M)
Capital Expenditures (CapEx)	$1M	$1M	$2M	$1M	$1M	$1M	$3M	$6M	$6M	$11M	$9M	$5M	$2M	$2M	$1M	$1M
Free Cash Flow (FCF)	($201M)	($122M)	($107M)	($80M)	($56M)	($109M)	($168M)	($154M)	($193M)	($172M)	($75M)	($37M)	($34M)	($26M)	($18M)	($12M)
FCF Margin %	—	—	-4159.5%	-510.8%	-1165.4%	-1912.4%	-1493.2%	-1046.7%	-1507.9%	-1489.1%	-942.8%	-16892.3%	-13246.2%	-10526.6%	-7987.3%	-7081.8%
Dividends Paid	—	—	—	—	—	—	$0M	$0M	$0M	$0M	$0M	$1M	$5M	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

DBVT Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	($83M)	($49M)	($35M)	($32M)	($34M)	($20M)	($12M)	($22M)
Capital Expenditures (CapEx)	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Free Cash Flow (FCF)	($83M)	($50M)	($36M)	($33M)	($34M)	($20M)	($12M)	($23M)
FCF Margin %	—	—	—	—	—	-3850.9%	—	-2131.8%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

DBVT Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31
Total Assets	$223M	$234M	$66M	$183M	$247M	$146M	$272M	$272M	$235M	$250M	$317M	$410M	$198M	$85M	$73M	$27M
Cash & Cash Equivalents	$175M	$194M	$32M	$141M	$209M	$77M	$196M	$193M	$168M	$194M	$283M	$386M	$181M	$72M	$65M	$19M
Total Liabilities	$63M	$65M	$38M	$43M	$52M	$47M	$67M	$79M	$69M	$67M	$49M	$25M	$16M	$11M	$6M	$7M
Total Debt (Short + Long-Term)	$14M	$16M	$2M	$2M	$9M	$4M	$5M	$5M	$5M	$6M	$5M	$6M	$4M	$2M	$1M	$0M
Total Shareholders' Equity	$160M	$169M	$27M	$140M	$194M	$99M	$205M	$193M	$166M	$183M	$268M	$384M	$182M	$74M	$67M	$20M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive DBVT viewer.

Other Companies in BIOTECHNOLOGY

PHAR · Pharming Group NV — $811 million
CTMX · CytomX Therapeutics Inc — $808 million
CLYM · Climb Bio Inc — $807 million
FDMT · 4D Molecular Therapeutics Inc — $779 million
ACHV · Achieve Life Sciences Inc — $776 million
CBIO · Crescent Biopharma, Inc. — $776 million
DSGN · Design Therapeutics Inc — $766 million
NGNE · Neurogene Inc — $758 million

← DBV All “D” companies DBX →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.